Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer
Objective: To dissect the correlated hematologic markers that reflect the clinical outcome or treatment response in patients receiving dose-dense chemotherapy with a combination of platinum (cisplatin or carboplatin) and paclitaxel. Materials and Methods: From 2009 to 2014, we enrolled 55 ovarian ca...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-06-01
|
| Series: | Taiwanese Journal of Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1028455916300390 |
| _version_ | 1811326876563537920 |
|---|---|
| author | Chueh-Yi Huang Yuh-Cheng Yang Kung-Liahng Wang Tze-Chien Chen Jen-Ruei Chen Chia-Sui Weng Hung-Ju Chien Chih-Long Chang |
| author_facet | Chueh-Yi Huang Yuh-Cheng Yang Kung-Liahng Wang Tze-Chien Chen Jen-Ruei Chen Chia-Sui Weng Hung-Ju Chien Chih-Long Chang |
| author_sort | Chueh-Yi Huang |
| collection | DOAJ |
| description | Objective: To dissect the correlated hematologic markers that reflect the clinical outcome or treatment response in patients receiving dose-dense chemotherapy with a combination of platinum (cisplatin or carboplatin) and paclitaxel.
Materials and Methods: From 2009 to 2014, we enrolled 55 ovarian cancer patients (total 67 courses) including first-line, persistent, platinum-sensitive, or platinum-resistant disease in MacKay Memorial Hospital, Taipei, Taiwan. Weekly pretreatment complete blood counts and calculated ratios [platelet/neutrophil ratio, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), neutrophil/monocyte ratio, platelet/monocyte ratio, lymphocyte/monocyte ratio] during dose-dense chemotherapy were collected. By grouping these hematologic biomarkers into three different response subgroups (responsive, stable, and nonresponsive) according to CA125 trend, the data were analyzed using one-way analysis of variance, and using post hoc-Tukey test for comparing each other. A p value < 0.05 was considered to be statistically significant.
Results: Absolute counts of lymphocytes and platelets, PLR, platelet/neutrophil ratio, platelet/monocyte ratio (all p < 0.001), and NLR (p=0.013) had statistically significant differences. Moreover, using box-and-whisker plot, absolute count of lymphocyte, PLR, and NLR showed most remarkable discrepancy in responsive, stable, and nonresponsive patients. Subgroup analysis for primary, platinum-sensitive, and platinum-resistant patients further revealed that PLR and NLR were significantly correlated to the outcome of dose-dense chemotherapy.
Conclusion: Lower PLR or lower NLR had better treatment response for dose-dense chemotherapy and are possible markers for representing treatment response in dose-dense chemotherapy. For a clinician, this is useful for timing when to switch to another chemotherapy regimen. |
| first_indexed | 2024-04-13T14:57:05Z |
| format | Article |
| id | doaj.art-5639896efb9041fc879c3dc098af6084 |
| institution | Directory Open Access Journal |
| issn | 1028-4559 |
| language | English |
| last_indexed | 2024-04-13T14:57:05Z |
| publishDate | 2016-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Taiwanese Journal of Obstetrics & Gynecology |
| spelling | doaj.art-5639896efb9041fc879c3dc098af60842022-12-22T02:42:25ZengElsevierTaiwanese Journal of Obstetrics & Gynecology1028-45592016-06-0155340540910.1016/j.tjog.2016.04.017Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancerChueh-Yi Huang0Yuh-Cheng Yang1Kung-Liahng Wang2Tze-Chien Chen3Jen-Ruei Chen4Chia-Sui Weng5Hung-Ju Chien6Chih-Long Chang7Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, TaiwanDepartment of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, TaiwanDepartment of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, TaiwanDepartment of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, TaiwanDepartment of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, TaiwanDepartment of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, TaiwanDepartment of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, TaiwanDepartment of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, TaiwanObjective: To dissect the correlated hematologic markers that reflect the clinical outcome or treatment response in patients receiving dose-dense chemotherapy with a combination of platinum (cisplatin or carboplatin) and paclitaxel. Materials and Methods: From 2009 to 2014, we enrolled 55 ovarian cancer patients (total 67 courses) including first-line, persistent, platinum-sensitive, or platinum-resistant disease in MacKay Memorial Hospital, Taipei, Taiwan. Weekly pretreatment complete blood counts and calculated ratios [platelet/neutrophil ratio, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), neutrophil/monocyte ratio, platelet/monocyte ratio, lymphocyte/monocyte ratio] during dose-dense chemotherapy were collected. By grouping these hematologic biomarkers into three different response subgroups (responsive, stable, and nonresponsive) according to CA125 trend, the data were analyzed using one-way analysis of variance, and using post hoc-Tukey test for comparing each other. A p value < 0.05 was considered to be statistically significant. Results: Absolute counts of lymphocytes and platelets, PLR, platelet/neutrophil ratio, platelet/monocyte ratio (all p < 0.001), and NLR (p=0.013) had statistically significant differences. Moreover, using box-and-whisker plot, absolute count of lymphocyte, PLR, and NLR showed most remarkable discrepancy in responsive, stable, and nonresponsive patients. Subgroup analysis for primary, platinum-sensitive, and platinum-resistant patients further revealed that PLR and NLR were significantly correlated to the outcome of dose-dense chemotherapy. Conclusion: Lower PLR or lower NLR had better treatment response for dose-dense chemotherapy and are possible markers for representing treatment response in dose-dense chemotherapy. For a clinician, this is useful for timing when to switch to another chemotherapy regimen.http://www.sciencedirect.com/science/article/pii/S1028455916300390dose-dense chemotherapyhematological markersovarian cancer |
| spellingShingle | Chueh-Yi Huang Yuh-Cheng Yang Kung-Liahng Wang Tze-Chien Chen Jen-Ruei Chen Chia-Sui Weng Hung-Ju Chien Chih-Long Chang Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer Taiwanese Journal of Obstetrics & Gynecology dose-dense chemotherapy hematological markers ovarian cancer |
| title | Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer |
| title_full | Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer |
| title_fullStr | Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer |
| title_full_unstemmed | Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer |
| title_short | Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer |
| title_sort | possible surrogate marker for an effective dose dense chemotherapy in treating ovarian cancer |
| topic | dose-dense chemotherapy hematological markers ovarian cancer |
| url | http://www.sciencedirect.com/science/article/pii/S1028455916300390 |
| work_keys_str_mv | AT chuehyihuang possiblesurrogatemarkerforaneffectivedosedensechemotherapyintreatingovariancancer AT yuhchengyang possiblesurrogatemarkerforaneffectivedosedensechemotherapyintreatingovariancancer AT kungliahngwang possiblesurrogatemarkerforaneffectivedosedensechemotherapyintreatingovariancancer AT tzechienchen possiblesurrogatemarkerforaneffectivedosedensechemotherapyintreatingovariancancer AT jenrueichen possiblesurrogatemarkerforaneffectivedosedensechemotherapyintreatingovariancancer AT chiasuiweng possiblesurrogatemarkerforaneffectivedosedensechemotherapyintreatingovariancancer AT hungjuchien possiblesurrogatemarkerforaneffectivedosedensechemotherapyintreatingovariancancer AT chihlongchang possiblesurrogatemarkerforaneffectivedosedensechemotherapyintreatingovariancancer |